MCID: HPT001
MIFTS: 73

Hepatitis C

Categories: Rare diseases, Infectious diseases, Liver diseases, Gastrointestinal diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C 12 72 51 40 41 14 69
Hepatitis C, Chronic 41 69
Hepatitis C Infection 12
Chronic Hepatitis C 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 51
Viral Hepatitis C 12
Nanbh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1883
ICD10 32 B19.2 B19.20
ICD9CM 34 070.7
NCIt 46 C3098

Summaries for Hepatitis C

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis C, is caused by the hepatitis C virus (HCV). It usually spreads through contact with infected blood. It can also spread through sex with an infected person and from mother to baby during childbirth. Most people who are infected with hepatitis C don't have any symptoms for years. If you do get symptoms, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. A blood test can tell if you have it. Usually, hepatitis C does not get better by itself. The infection can last a lifetime and may lead to cirrhosis (scarring of the liver) or liver cancer. Medicines sometimes help, but side effects can be a problem. Serious cases may need a liver transplant. There is no vaccine for HCV. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c, chronic, is related to hepatitis c virus and cryoglobulinemia, familial mixed, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis C is SCARB1 (Scavenger Receptor Class B Member 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Miconazole and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 72 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 580)
# Related Disease Score Top Affiliating Genes
1 hepatitis c virus 32.9 CD81 CLDN1 CLDN6 CLDN9 DDX58 EIF2AK2
2 cryoglobulinemia, familial mixed 31.3 IFNA1 IFNA2
3 hepatitis 31.2 CD81 CLDN1 CLDN6 CLDN9 DDX58 EIF2AK2
4 viral hepatitis 31.1 GPT IFNA1 IFNA2
5 hepatitis b 31.1 GPT IFNA1 IFNA2 STAT1 TLR3
6 oral erosive lichen 30.4 IFNA1 IFNB1
7 west nile virus 30.0 DDX58 IFNA1 IRF3 TLR3
8 stomatitis 30.0 DDX58 EIF2AK2 IFNA1 IFNA2 LDLR
9 hepatitis e 29.9 DDX58 GPT TLR3
10 vaccinia 29.8 EIF2AK2 IFNA1 IFNB1 IRF3 IRF7
11 severe acute respiratory syndrome 29.6 IFNA1 IFNB1 IRF3 STAT1
12 japanese encephalitis 29.5 DDX58 IFNB1 STAT1 TLR3
13 kaposi sarcoma 29.4 IFNA1 IFNA2 IFNB1 IRF3 IRF7
14 encephalitis 29.4 DDX58 IRF3 TLR3
15 influenza 29.2 DDX58 EIF2AK2 IFNA1 IFNB1 IRF7 TLR3
16 measles 28.9 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 STAT1
17 chronic end-stage hepatitis c 12.0
18 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.0
19 hepatocellular carcinoma 11.5
20 liver disease 11.3
21 porphyria cutanea tarda 11.3
22 fatty liver disease 11.2
23 linear lichen planus 11.2
24 fibrillary glomerulonephritis 11.2
25 immunotactoid glomerulopathy 11.2
26 immunotactoid or fibrillary glomerulopathy 11.2
27 pars planitis 10.9
28 capillariasis 10.9
29 papular mucinosis 10.9
30 cryoglobulinemia 10.6
31 fibrosis of extraocular muscles, congenital, 1 10.6
32 lymphomatoid granulomatosis 10.5 IFNA1 IFNA2
33 squamous papillomatosis 10.5 IFNA1 IFNA2
34 fanconi anemia, complementation group c 10.5 EIF2AK2 IFNA1 STAT1
35 pediatric lymphoma 10.5 CD81 IRF3 IRF7
36 glomerulonephritis 10.4
37 zika fever 10.4 IFNB1 STAT1
38 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
39 lymphoma 10.4
40 la crosse encephalitis 10.4 DDX58 IFNB1 IRF3
41 microphthalmia with limb anomalies 10.4 IFNA1 IFNB1 STAT1
42 newcastle disease 10.4 DDX58 IFNA1 IFNB1 IRF3
43 porphyria 10.4
44 mouth disease 10.3 IFNA1 IRF3 JAK1 STAT1
45 rabies 10.3 IRF3 STAT1 TLR3
46 membranoproliferative glomerulonephritis 10.3
47 venezuelan equine encephalitis 10.3 IFNB1 IRF7 STAT1
48 thyroiditis 10.3
49 liver cirrhosis 10.3
50 vasculitis 10.3

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

GenomeRNAi Phenotypes related to Hepatitis C according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.02 CD81 CLDN1 GPT IRF3 IRF7

MGI Mouse Phenotypes related to Hepatitis C:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 IRF7 JAK1 CD81 LDLR DDX58 SCARB1
2 homeostasis/metabolism MP:0005376 9.97 IRF7 JAK1 CD81 CLDN1 LDLR DDX58
3 immune system MP:0005387 9.77 JAK1 CD81 LDLR DDX58 SCARB1 EIF2AK2
4 neoplasm MP:0002006 9.17 DDX58 EIF2AK2 STAT1 IFNAR1 TLR3 IFNAR2

Drugs & Therapeutics for Hepatitis C

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 571)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
4
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
5
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
8
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
10
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 143491-57-0 60877
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
12
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
13
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
14
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
15
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
16
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
17
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
18
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
19
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
20
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
21
Insulin Glargine Approved Phase 4 160337-95-1
22
Insulin-glulisine Approved Phase 4 207748-29-6
23
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
24
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
25
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
26
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
28
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
29
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
30
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
31
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 134678-17-4 60825
32
Zidovudine Approved Phase 4,Phase 1,Phase 2 30516-87-1 35370
33
Interferon alfacon-1 Approved, Investigational Phase 4,Phase 3,Phase 2 118390-30-0 9554198
34
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
35
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
36
Heroin Approved, Illicit, Investigational Phase 4,Phase 3 561-27-3 5462328
37
Nevirapine Approved Phase 4 129618-40-2 4463
38
Rifaximin Approved, Investigational Phase 4,Phase 2 80621-81-4 6436173
39
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
40
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
42
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
43
Losartan Approved Phase 4 114798-26-4 3961
44
Daclizumab Approved, Investigational Phase 4 152923-56-3
45
Iron Approved Phase 4,Phase 2 7439-89-6 23925
46
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
47
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
48
Nelfinavir Approved Phase 4 159989-64-7 64143
49
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
50
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 2181)

# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
3 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
4 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
5 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
6 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
7 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
8 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
9 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
10 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
11 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
12 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
13 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
14 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
15 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
16 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
17 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
18 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
19 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
20 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
21 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
22 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
23 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
24 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
25 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
26 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
27 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
28 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
29 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
30 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4 Cyclosporine;Tacrolimus
31 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
32 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
33 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4 Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
34 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
35 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4 Pegylated interferon alfa-2a
36 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
37 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4 cyclosporin (Neoral);tacrolimus (Prograf)
38 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
39 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
40 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
41 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
42 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
43 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
44 Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection Completed NCT02377856 Phase 4 pegylated interferon alpha 2a, ribavirin
45 Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin;Pegylated interferon and ribavirin
46 The Effect of Adding Metformin to the Treatment of Hepatitis C Completed NCT00560690 Phase 4 Metformin;pegylated interferon;Ribavirin
47 Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients Completed NCT00132210 Phase 4 pegylated interferon
48 Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C Completed NCT01596517 Phase 4 Peginterferon alfa-2a plus ribavirin for HCV genotype 1;Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
49 Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC Completed NCT00207363 Phase 4 Ribavirin, Peg interferon alfa 2b;induction therapy
50 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. Completed NCT00087633 Phase 4 peginterferon alfa-2a [Pegasys];Copegus

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

18
Liver

MalaCards organs/tissues related to Hepatitis C:

38
Liver, Testes, Kidney, T Cells, B Cells, Skin, Thyroid

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 6747)
# Title Authors Year
1
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
2
Correction: An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors. ( 29389963 )
2018
3
Training in emerging advances in chronic hepatitis C infection in Pakistan: the Teach - Pak project. ( 29445310 )
2018
4
Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. ( 29437963 )
2018
5
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
6
Plant-derived antivirals against hepatitis c virus infection. ( 29439720 )
2018
7
Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. ( 29432255 )
2018
8
Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )
2018
9
The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. ( 29411135 )
2018
10
Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )
2018
11
Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )
2018
12
Notes from the Field: Underreporting of Maternal Hepatitis C Virus Infection Status and the Need for Infant Testing - Oregon, 2015. ( 29447143 )
2018
13
The next wave of hepatitis C virus: The epidemic of intravenous drug use. ( 29427493 )
2018
14
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
15
Are we underestimating the quality of aviremic Hepatitis C positive kidneys? Time to reconsider. ( 29451354 )
2018
16
Atypical generalized morphea-like scleroderma occurring in a patient exposed to organic solvents and having chronic hepatitis C virus infection. ( 29451196 )
2018
17
Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy. ( 29272568 )
2018
18
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all? ( 29446138 )
2018
19
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? ( 29446143 )
2018
20
Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. ( 29437969 )
2018
21
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )
2018
22
Dissecting the decline of hepatitis C in first-time donors in England and Wales. ( 29441589 )
2018
23
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. ( 29435197 )
2018
24
Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. ( 29445495 )
2018
25
Hepatitis C virus core+1/ARFP modulates Cyclin D1/pRb pathway and promotes carcinogenesis. ( 29444947 )
2018
26
Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )
2018
27
Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study. ( 29345111 )
2018
28
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )
2018
29
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply. ( 29446133 )
2018
30
Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. ( 29416725 )
2018
31
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. ( 29439971 )
2018
32
Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. ( 29451090 )
2018
33
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. ( 29318374 )
2018
34
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan. ( 29429413 )
2018
35
Coexistent Ipsilateral Internal Carotid Artery Occlusion and Cerebral Venous Thrombosis in Hepatitis C. ( 29349091 )
2018
36
Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )
2018
37
Spontaneous bacterial peritonitis due to Helicobacter pylori in a cirrhotic patient with human immunodeficiency virus and hepatitis C virus coinfection. ( 29429754 )
2018
38
Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia. ( 28088084 )
2017
39
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. ( 28521955 )
2017
40
Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. ( 27930836 )
2017
41
Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. ( 28081037 )
2017
42
T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. ( 27809352 )
2017
43
Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report. ( 28810602 )
2017
44
Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )
2017
45
Community-based molecular epidemiology study of hepatitis C virus infection in injection drug users. ( 28943522 )
2017
46
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
47
Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus-coinfected patient with cure of hepatitis C by direct-acting antiviral agents. ( 28960371 )
2017
48
Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). ( 28935852 )
2017
49
Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. ( 28797039 )
2017
50
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. ( 28533673 )
2017

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CD81 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1
2
Show member pathways
13.49 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
3
Show member pathways
13.4 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
4
Show member pathways
13.02 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
5
Show member pathways
13 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
6
Show member pathways
12.84 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
7 12.81 IFNA1 IFNA2 IFNAR1 IFNAR2 JAK1 STAT1
8
Show member pathways
12.71 DDX58 IFNA1 IFNA2 IFNB1 IRF3 IRF7
9 12.62 DDX58 IFNA1 IRF3 IRF7 JAK1 STAT1
10
Show member pathways
12.58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
11
Show member pathways
12.49 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
12
Show member pathways
12.49 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
13
Show member pathways
12.43 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
14
Show member pathways
12.39 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
15
Show member pathways
12.37 DDX58 IRF3 IRF7 TLR3
16
Show member pathways
12.3 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
17 12.26 DDX58 EIF2AK2 IRF3 JAK1
18 12.25 EIF2AK2 IRF3 IRF7 JAK1
19
Show member pathways
12.25 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
20 12.24 IFNA1 IFNA2 IFNB1 JAK1 STAT1
21
Show member pathways
12.23 IRF3 JAK1 STAT1 TLR3
22 12.23 CD81 CLDN1 CLDN6 CLDN9 DDX58 EIF2AK2
23
Show member pathways
12.22 IFNB1 IRF3 IRF7 TLR3
24 12.18 IFNA1 IFNA2 IFNB1 IRF3 IRF7
25
Show member pathways
12.18 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
26 12.07 IFNAR1 IFNAR2 IFNB1 JAK1 STAT1
27 11.91 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
28
Show member pathways
11.86 JAK1 STAT1 TLR3
29
Show member pathways
11.8 JAK1 STAT1 TLR3
30 11.62 IFNAR1 IFNAR2 JAK1 STAT1
31 11.49 EIF2AK2 IFNA2 IFNB1 JAK1 STAT1
32 11.43 IFNA1 IFNA2 IFNB1
33
Show member pathways
11.43 EIF2AK2 JAK1 STAT1
34
Show member pathways
11.39 IFNL4 JAK1 STAT1
35 10.95 JAK1 STAT1
36 10.87 IFNAR1 IFNB1
37
Show member pathways
10.64 DDX58 EIF2AK2 IFNA2 IFNAR1 IFNAR2 IRF3

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 CD81 CLDN1 IFNAR1 IFNAR2 LDLR SCARB1
2 endolysosome membrane GO:0036020 8.96 LDLR TLR3
3 bicellular tight junction GO:0005923 8.92 CLDN1 CLDN6 CLDN9 DDX58

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.99 CD81 IFNA2 IFNAR2 IFNB1
2 defense response GO:0006952 9.93 IFNA1 IFNA2 IFNB1 TLR3
3 response to virus GO:0009615 9.91 DDX58 EIF2AK2 IFNAR1 IFNAR2 IFNB1 IRF7
4 viral entry into host cell GO:0046718 9.88 CD81 CLDN1 CLDN6 CLDN9 LDLR SCARB1
5 cellular response to interferon-gamma GO:0071346 9.86 CLDN1 STAT1 TLR3
6 B cell differentiation GO:0030183 9.84 IFNA1 IFNA2 IFNB1
7 humoral immune response GO:0006959 9.83 IFNA1 IFNA2 IFNB1
8 interferon-gamma-mediated signaling pathway GO:0060333 9.83 IRF3 IRF7 JAK1 STAT1
9 positive regulation of type I interferon production GO:0032481 9.81 IRF3 IRF7 TLR3
10 response to exogenous dsRNA GO:0043330 9.8 DDX58 IFNA1 IFNA2 IFNB1 IRF3 TLR3
11 B cell proliferation GO:0042100 9.78 IFNA1 IFNA2 IFNB1
12 positive regulation of interferon-beta production GO:0032728 9.78 DDX58 IRF3 IRF7 TLR3
13 JAK-STAT cascade GO:0007259 9.77 IFNAR1 IFNAR2 STAT1
14 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.77 IRF3 IRF7 TLR3
15 positive regulation of interferon-alpha production GO:0032727 9.76 DDX58 IRF3 IRF7 STAT1
16 cell-cell junction organization GO:0045216 9.75 CLDN1 CLDN6 CLDN9
17 T cell activation involved in immune response GO:0002286 9.74 IFNA1 IFNA2 IFNB1
18 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.73 IFNA1 IFNA2 IFNB1
19 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.72 CLDN1 CLDN6 CLDN9
20 natural killer cell activation involved in immune response GO:0002323 9.71 IFNA1 IFNA2 IFNB1
21 regulation of type I interferon-mediated signaling pathway GO:0060338 9.7 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
22 defense response to virus GO:0051607 9.7 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR2 IFNB1
23 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.69 CD81 LDLR
24 regulation of type I interferon production GO:0032479 9.69 IRF3 IRF7
25 cellular response to exogenous dsRNA GO:0071360 9.69 DDX58 IFNB1 TLR3
26 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.68 JAK1 STAT1
27 positive regulation of triglyceride biosynthetic process GO:0010867 9.68 LDLR SCARB1
28 response to interferon-alpha GO:0035455 9.67 EIF2AK2 IFNAR2
29 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.67 IRF3 IRF7
30 response to interferon-beta GO:0035456 9.67 IFNAR2 STAT1
31 cellular response to interferon-beta GO:0035458 9.67 IFNB1 STAT1 TLR3
32 negative regulation of T cell differentiation GO:0045581 9.65 IFNA2 IFNB1
33 cholesterol import GO:0070508 9.65 LDLR SCARB1
34 cellular response to dsRNA GO:0071359 9.64 IRF3 TLR3
35 detection of virus GO:0009597 9.63 DDX58 TLR3
36 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNA2 IFNB1
37 type I interferon biosynthetic process GO:0045351 9.62 IRF3 IRF7
38 MDA-5 signaling pathway GO:0039530 9.61 IRF3 IRF7
39 regulation of phosphatidylcholine catabolic process GO:0010899 9.58 LDLR SCARB1
40 type I interferon signaling pathway GO:0060337 9.28 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 CD81 DDX58 IFNB1 IRF3 IRF7 STAT1
42 innate immune response GO:0045087 10.09 DDX58 EIF2AK2 IFNA1 IFNA2 IFNL4 IRF3
43 immune system process GO:0002376 10.08 DDX58 EIF2AK2 IRF3 IRF7 TLR3
44 viral process GO:0016032 10 CD81 CLDN1 CLDN6 CLDN9 DDX58 EIF2AK2

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.73 IFNA1 IFNA2 IFNB1 IFNL4
2 identical protein binding GO:0042802 9.61 CLDN1 CLDN6 CLDN9 DDX58 EIF2AK2 IRF3
3 double-stranded RNA binding GO:0003725 9.58 DDX58 EIF2AK2 TLR3
4 cytokine receptor binding GO:0005126 9.5 IFNA1 IFNA2 IFNB1
5 low-density lipoprotein particle binding GO:0030169 9.46 LDLR SCARB1
6 CCR5 chemokine receptor binding GO:0031730 9.37 JAK1 STAT1
7 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
8 type I interferon receptor activity GO:0004905 9.26 IFNAR1 IFNAR2
9 virus receptor activity GO:0001618 9.1 CD81 CLDN1 CLDN6 CLDN9 LDLR SCARB1

Sources for Hepatitis C

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA